PlaqueTec has collaborated with the Babraham Institute's Welch lab in evaluating the drugability of pro-inflammatory protein under BIOPATTERN trial focused on endotyping coronary artery disease (CAD). The parties have previously asserted the potential of pro-inflammatory protein to be targeted by small-molecule drugs in a human cell-culture model.
Based in the UK, PlaqueTec is focused on the development and application of endotype-specific biomarkers to develop novel treatments for CAD. PlaqueTec employs its proprietary Liquid Biopsy System to capture biomarkers directly from coronary arteries to provide a deeper understanding of the disease's nature and develop precise treatments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.